Caris Life Sciences (CAI) Other Operating Expenses (2024 - 2026)

Caris Life Sciences' Other Operating Expenses history runs 3 years deep, the most recent figure standing at $106.1 million for Q1 2026.

• On a quarterly basis, Other Operating Expenses rose 22.11% year-over-year to $106.1 million in Q1 2026; TTM through Mar 2026 was $425.6 million, a 34.22% increase from a year earlier, with the FY2025 full-year figure at $440.4 million, up 26.76% from the prior year.
• Other Operating Expenses retreated to $106.1 million in Q1 2026 per CAI's latest filing, from $116.1 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $116.1 million in Q4 2025 and bottomed at $58.1 million in Q4 2024.
• The 3-year median for Other Operating Expenses is $90.0 million (2024), against an average of $92.8 million.
• Biggest YoY gain for Other Operating Expenses was 100.03% in 2025; the steepest drop was 6.28% in 2025.
• Year by year, Other Operating Expenses stood at $58.1 million in 2024, then soared by 100.03% to $116.1 million in 2025, then decreased by 8.6% to $106.1 million in 2026.
• Per Business Quant, the three latest CAI Other Operating Expenses figures stand at $106.1 million (Q1 2026), $116.1 million (Q4 2025), and $110.6 million (Q3 2025).